abstract |
The present invention relates to benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2) of formula I, for use in the treatment of Parkinson's disease levodopa-induced dyskinesia, wherein R1-R27 are hydrogen or deuterium; and at least one of R1-R27 is deuterium. |